IND26326 | 380843-31-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: IND26326
• 英文别名: 1-(4-Chlorophenyl)-2-(2-imino-3-methyl-benzimidazol-1-yl)ethanone；1-(4-chlorophenyl)-2-(2-imino-3-methylbenzimidazol-1-yl)ethanone
• CAS: 380843-31-2
• 化学式: C₁₆H₁₄ClN₃O
• 分子量: 299.76
• InChiKey: JMTJJCUAYVXGER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  47.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2'-溴-4-氯苯乙酮 、 2-氨-1-甲基苯咪唑 以 N,N-二甲基甲酰胺 为溶剂， 以96%的产率得到IND26326
  参考文献：
  名称：

  Lead identification of 2-iminobenzimidazole antagonists of the chemokine receptor CXCR3

  摘要：

  Modi. cation of a 2-iminobenzimidazole series derived from an HTS hit resulted in compounds with improved in-vitro species selectivity. Incorporation of an 8-quinoline amide and conformational rigidification of an aliphatic tether furnished potent compounds suitable for further lead optimization. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.02.049

文献信息

• 2-Imino-benzimidazoles
  申请人：Roth P. Gregory

  公开号：US20070232673A1

  公开（公告）日：2007-10-04

  Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

  本发明涉及式（I）的新化合物或其药学上可接受的盐、前药和生物活性代谢物，其中取代基如本文所定义，其作为治疗剂具有用处。
• NOVEL ANTIPRION COMPOUNDS
  申请人：The Regents of the University of California

  公开号：US20140329863A1

  公开（公告）日：2014-11-06

  Described herein are novel compositions and methods of treatment addressing diseases such as neurodegenerative diseases, including prion diseases and Alzheimer's disease.

  本文描述了一种新的组合物和治疗方法，用于治疗神经退行性疾病，包括朊病和阿尔茨海默病。
• Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3
  作者：Martin E. Hayes、Grier A. Wallace、Pintipa Grongsaard、Agnieszka Bischoff、Dawn M. George、Wenyan Miao、Michael J. McPherson、Robert H. Stoffel、David W. Green、Gregory P. Roth

  DOI：10.1016/j.bmcl.2008.01.074

  日期：2008.3

  High-throughput screening identified a low molecular weight antagonist of CXCR3 displaying micromolar activity in a membrane filtration-binding assay. Systematic modi. cation of the benzimidazole core and tethered acetophenone moiety established tractable SAR of analogs with improved physicochemical properties and sub-micromolar activity across both human and murine receptors. (c) 2008 Elsevier Ltd. All rights reserved.
• [EN] NOVEL ANTIPRION COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS D'ANTIPRION
  申请人：UNIV CALIFORNIA

  公开号：WO2013033037A2

  公开（公告）日：2013-03-07

  Described herein are novel compositions and methods of treatment addressing diseases such as neurodegenerative diseases, including prion diseases and Alzheimer's disease.
• Lead identification of 2-iminobenzimidazole antagonists of the chemokine receptor CXCR3
  作者：Martin E. Hayes、Eric C. Breinlinger、Grier A. Wallace、Pintipa Grongsaard、Wenyan Miao、Michael J. McPherson、Robert H. Stoffel、David W. Green、Gregory P. Roth

  DOI：10.1016/j.bmcl.2008.02.049

  日期：2008.4

  Modi. cation of a 2-iminobenzimidazole series derived from an HTS hit resulted in compounds with improved in-vitro species selectivity. Incorporation of an 8-quinoline amide and conformational rigidification of an aliphatic tether furnished potent compounds suitable for further lead optimization. (C) 2008 Elsevier Ltd. All rights reserved.